【讨论】如何和SCI文献作者进行email交流
发布于 2010-03-22 · 浏览 5140 · IP 广东广东
这个帖子发布于 15 年零 61 天前，其中的信息可能已发生改变或有所发展。
申请课题需要阅读文献，写文章碰到问题需要阅读文献
在阅读文献中的时候难免产生问题，如何和国外的通讯作者进行联系并讨论相关的学术内容？如何注意措辞？如何描述相关内容？
大家有经验吗？
最近，准备了两个片段（准备和MSKCC和Harvard的两个大牛联系），发给别人看，说太“chinglish”了。
大家对此有什么经验？请大家一起来讨论。
I am very impressive about your work in JCO(2006,26:4293-4300), which indicates that basal pERK level may be a candidate biomarker for prediction of Sorafenib s efficacy in HCC.
You must have got to know a recent paper from China, an invtro study, which provides additional evidence to support your conclusion about pERK(BMC Medicine, 2009,7:42). Zhu, from Harvard, appreciated that work and wrote a comment assay on this study(BMC Medicine, 2009,7:41).
I have some questions about your job. As you know, the etiology factors such as HBV or HCV infection can have an effect on Raf/MEK/ERK axis. Have you investigate the ratio of HBV or HCV infection or even other etiology factor such as alcohol in this 33 patients? Most of patients with HCC have HBV infection in China, so it could be an interesting problem.
Since 2006, you must have more patients administrated to receive sorafenib as the main treatment. Have you continued to investigate the possible prediction use of basal pERK level?
I am a surgeon, from Department of Hepatobiliary Surgery, the First Affiliated Hospital, Sun Yat-sen University of Medical School. We already have about 35 patients who received sorafenib administration since Dec, 2008. We can have about 20 tissue samples to have a IHC staining of pERK. We are going to find more cases from our research partner, Sun Yat-sen University Cancer Center. They have about 50 patients who received sorafenib till date. I am wondering whether we could do something to use the patients resource.
The confirmed effect of Sorafenib in HCC is a breakthrough in the study of HCC. Searching for the predictor biomarker is an important job. We are designing a series of experiments in this field. Do you have some suggestions?
I am very impressive about your comment on BMC Medicine(BMC Medicine, 2009,7:41), which indicates that basal pERK level may be a candidate biomarker to predict sorafenib s efficacy in HCC. And I am wondering that if you have time to answer my questions about it.
As you know, the etiology factors such as HBV or HCV infection can have an effect on Raf/MEK/ERK axis. Do you think that whether pERK can have different expression according to their different etiology factor?
I ve noticed that a recent study have partially answer this question(J hepatol, 2008,48:83-90). They concluded that ERK 1/2 activation correlated statistically with the presence of HCV infection and pERK expression shows a significant correlation with a decreased OS in HCC. But what is the data on HCC patients with HBV infection? Is it the same? There is no answer.
In Abou-alfa s study(JCO, 2006,26:4293-4300) , basal pERK level was investigated by IHC staining in 33 patients. But they have not distinguish the etiology factor in the enrolled patient group.
I am a surgeon, from Department of Hepatobiliary Surgery, the First Affiliated Hospital, Sun Yat-sen University of Medical School. We already have about 35 patients who received sorafenib administration since Dec, 2008. We can have about 20 tissue samples to have a IHC staining of pERK. We are going to find more cases from our research partner, Sun Yat-sen University Cancer Center. They have about 50 patients who received sorafenib till date. I am wondering whether we could do something to use the patients resource.
The confirmed effect of Sorafenib in HCC is a breakthrough in the study of HCC. Searching for the predictor biomarker is an important job. We are designing a series of experiments in this field. Do you have some suggestions?
在阅读文献中的时候难免产生问题，如何和国外的通讯作者进行联系并讨论相关的学术内容？如何注意措辞？如何描述相关内容？
大家有经验吗？
最近，准备了两个片段（准备和MSKCC和Harvard的两个大牛联系），发给别人看，说太“chinglish”了。
大家对此有什么经验？请大家一起来讨论。
I am very impressive about your work in JCO(2006,26:4293-4300), which indicates that basal pERK level may be a candidate biomarker for prediction of Sorafenib s efficacy in HCC.
You must have got to know a recent paper from China, an invtro study, which provides additional evidence to support your conclusion about pERK(BMC Medicine, 2009,7:42). Zhu, from Harvard, appreciated that work and wrote a comment assay on this study(BMC Medicine, 2009,7:41).
I have some questions about your job. As you know, the etiology factors such as HBV or HCV infection can have an effect on Raf/MEK/ERK axis. Have you investigate the ratio of HBV or HCV infection or even other etiology factor such as alcohol in this 33 patients? Most of patients with HCC have HBV infection in China, so it could be an interesting problem.
Since 2006, you must have more patients administrated to receive sorafenib as the main treatment. Have you continued to investigate the possible prediction use of basal pERK level?
I am a surgeon, from Department of Hepatobiliary Surgery, the First Affiliated Hospital, Sun Yat-sen University of Medical School. We already have about 35 patients who received sorafenib administration since Dec, 2008. We can have about 20 tissue samples to have a IHC staining of pERK. We are going to find more cases from our research partner, Sun Yat-sen University Cancer Center. They have about 50 patients who received sorafenib till date. I am wondering whether we could do something to use the patients resource.
The confirmed effect of Sorafenib in HCC is a breakthrough in the study of HCC. Searching for the predictor biomarker is an important job. We are designing a series of experiments in this field. Do you have some suggestions?
I am very impressive about your comment on BMC Medicine(BMC Medicine, 2009,7:41), which indicates that basal pERK level may be a candidate biomarker to predict sorafenib s efficacy in HCC. And I am wondering that if you have time to answer my questions about it.
As you know, the etiology factors such as HBV or HCV infection can have an effect on Raf/MEK/ERK axis. Do you think that whether pERK can have different expression according to their different etiology factor?
I ve noticed that a recent study have partially answer this question(J hepatol, 2008,48:83-90). They concluded that ERK 1/2 activation correlated statistically with the presence of HCV infection and pERK expression shows a significant correlation with a decreased OS in HCC. But what is the data on HCC patients with HBV infection? Is it the same? There is no answer.
In Abou-alfa s study(JCO, 2006,26:4293-4300) , basal pERK level was investigated by IHC staining in 33 patients. But they have not distinguish the etiology factor in the enrolled patient group.
I am a surgeon, from Department of Hepatobiliary Surgery, the First Affiliated Hospital, Sun Yat-sen University of Medical School. We already have about 35 patients who received sorafenib administration since Dec, 2008. We can have about 20 tissue samples to have a IHC staining of pERK. We are going to find more cases from our research partner, Sun Yat-sen University Cancer Center. They have about 50 patients who received sorafenib till date. I am wondering whether we could do something to use the patients resource.
The confirmed effect of Sorafenib in HCC is a breakthrough in the study of HCC. Searching for the predictor biomarker is an important job. We are designing a series of experiments in this field. Do you have some suggestions?
最后编辑于 2022-10-09 · 浏览 5140
16 16 点赞
